DOCSLIB.ORG

The Nucleus May 2021 the Northeastern Section of the American- Chemical Society, Inc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Nucleus May 2021 the Northeastern Section of the American- Chemical Society, Inc DED UN 18 O 98 F http://www.nesacs.org N Y O T R E I T H C E N O A E S S S L T A E A C R C I N S M S E E H C C T N May 2021 Vol. XCIX, No. 7 IO CA N • AMERI 2021 NESACS Election Candidate Statements Olaplex v. L’Oréal Problems with pharmaceutical and consumer product formulation claims ACS Scholar’s Experiences An ACS Scholar at M.I.T. Strem Chemicals Acquired Ascensus is new owner Bill Carroll, 2005 ACS President Strem Chemicals Acquired - Ascensus is new owner By Craig Sergeant It was with great surprise that I recently learned that long-time company. Thereafter, Alfa Products was sold to Johnson entrepreneur and local Massachusetts resident, Mike Strem, Matthey to merge with their Aesar chemical catalog business, had sold Strem Chemicals, Inc. During my time at Alfa Aesar and become Alfa Aesar, Inc., which was then sold to Thermo and Thermo Fisher Scientific, we always thought of Strem Fisher Scientific in 2015. Chemicals as an excellent and high quality provider of spe- Sodium borohydride production continued with Morton In- cialty chemicals, especially inorganics and organometallics. ternational when Rohm and Haas (remember them?) acquired I even had the chance to visit its facility in 2018 in Newbury- Morton in 1999. It was after Dow had acquired Rohm and port with some of my colleagues. We all were very impressed Haas in 2009, what is now Ascensus bought the sodium boro- with the excellent staff and manufacturing equipment. As any- hydride production business in 2015 from Dow. one who has been in the fine chemicals business knows, it is a very small world, and often a competitor is also a vendor. At this point, we need to bring Strem Chemicals back into this As much as we competed with Strem Chemicals, we also story. As long-time and recently retired Purchasing Manager would purchase reagents as needed to satisfy our customer’s for Alfa Aesar, Patti Ranta, recently related to me, in 1964, requirements. Mike Strem started out in Danvers producing reagents in the same building off Route 114 in Danvers as the Metal Hydrides Speaking of a small world, the acquiring company, Ascensus business, and would put the product in the truck before driving Specialties LLC, also has a very interesting history that starts around the building to deliver to the Alfa Products chemical back in 1957 here in New England, in Danvers, MA, when catalog business. Alfa was purchasing from Strem from the sodium borohydride was first commercially produced at a fa- very beginning! cility owned by Metal Hydrides, Inc. (Metal Hydrides itself has a fascinating history. Founded in the mid-1930s, it pur- It is only fair that I quote a bit from the press release about chased land in Beverly, MA, in 1939 to become a major re- the acquisition of Strem Chemicals. Mike Strem, the Founder finer of uranium-238 for the Manhattan Project during World of Strem Chemicals, related, “We thoughtfully chose Ascen- War II. I still have a set of Organic Syntheses published by sus as the partner for the next phase of Strem’s growth. Our Wiley with stamps for the Metal Hydrides company library.) employees’ interests and well-being have been my top priority, It is here where things get interesting for me personally. In and the strong cultural fit will provide opportunities for our 1962, Alfred Bader, founder of Aldrich Chemicals, entered his team. The additional resources and global reach of Ascensus company into a 50:50 joint venture with Metal Hydrides for will deliver Strem’s strong capabilities to an even broader au- the production of smaller catalog quantities of inorganic fine dience of customers.” chemicals. This led to the establishment of Alfa Inorganics Another well-known aspect of Strem Chemicals has been the (yes, Alfa, not Alpha due to Alfred Bader’s influence). In excellent morale of its employees. When I met them at trade 1965, Metal Hydrides became the Ventron Corporation, shows, or during that visit years ago in Newburyport, I could which, in turn, was purchased by the Thiokol Corporation and easily see that Mike Strem had made employee well-being a then became Morton Thiokol, Inc., in the early 1980s after high priority. I therefore, indeed, believe Mike Strem when merging with Morton International. This is, indeed, the same he says that his employees’ interests are a top priority. Having Morton Salt that you can buy today in your local supermar- been through an acquisition myself, I can truly understand the ket. anxiety that comes with it. I certainly wish all the best for the It was until about 1989 that Alfa Products and the large pro- employees in the Newburyport facility and much success to duction facility for sodium borohydride existed in the same Ascensus Specialties. u 2 The Nucleus May 2021 The Northeastern Section of the American- Chemical Society, Inc. Contents Office: Anna Singer, 12 Corcoran Road, Burlington, MA 01803 (Voice or FAX) (781) 272-1966. Strem Chemicals Acquired - Ascensus is new owner ___________2 e-mail: [email protected] By Craig Sergeant NESACS Homepage: http://www.NESACS.org New ACS Membership Options Coming in 2022 ______________4 Officers 2021 Chair Raj (SB) Rajur May Monthly Meeting ___________________________________5 Creagen Inc. Bill Carroll, 2005 ACS President, will speak at the Education Night Meeting 299 Washington St, Woburn, MA 01801 (781)-938-1122 MedChem Meeting______________________________________6 [email protected] Chair-Elect Matt Clark of XChem will be the speaker Carol Mulrooney GSK NESACS Election _______________________________________7 200 Cambridgepark Drive, 6th floor, Candidate Biographies and Statements Cambridge, MA 02140 [email protected] The Federal Circuit Adds Color to Formulation Claims in Olaplex v. Immediate Past Chair Anna W. Sromek L’Oréal ______________________________________________25 115 Mill Street By Philip J. Hamzik Belmont, MA 02478 [email protected] Secretary Call for Nominations for Richards Medal ___________________25 Michael Singer Millipore-Sigma ACS Scholar Discusses Her Experiences and Goals___________26 400 Summit Drive, Burlington, MA 01803 By Eleane Lema (781)-229-7037 [email protected] From the High School Classroom 26 Treasurer _________________________ Ashis Saha By Steve Lantos 67 Bow St. Arlington, MA 02474-2744 2020 ACS National Awards Ceremony _____________________28 (978)-212-5462 Archivist Spring 2021 Virtual Regional Meetings ____________________29 Ken Mattes Trustees Dorothy J. Phillips, Ruth Tanner, Catherine E. ACS Member-Get-A-Member _____________________________29 Costello Directors-at-Large ACS Webinars ________________________________________30 John M. Burke, David Harris, Mark Tebbe, James U. Piper, John Neumeyer Cover: Bill Carroll, 2005 ACS President, presenting at the May Monthly Councilors/Alternate Councilors Meeting. Term Ends 12/31/2021 Dr. Catherine Costello Dr. Daljit Matharu Editorial Deadlines: September 2021 Issue: August 1, 2021 Dr. Ruth Tanner Dr. Raj (SB) Rajur Dr. Andrew Scholte Dr. Stephen Canham October 2021 Issue: September 1, 2021 Dr. Kenneth Mattes Dr. Ray Lam Dr. Morton Z. Hoffman VACANT Term Ends 12/31/2022 Dr. Lisa Marcaurelle Dr. Mary A. Mahaney Dr. Mary Jane Shultz Dr. Jens Breffke Dr. Malika Jeffries-El Dr. Kap-Sun Yeung The Nucleus is published monthly, except June and August, by the Northeastern Section of the American Dr. Sofia Santos Dr. Hicham Fenniri Chemical Society, Inc. Forms close for advertising on the 1st of the month of the preceding issue. Text Dr. Sonia Strah-Pleynet Dr. Ashis Saha must be received by the Editor four weeks before the date of issue. Dr. Thomas R. Gilbert Dr. Natalie LaFranzo Term Ends 12/31/2023 Editor: Craig D. Sergeant, 11 Dearborn Road, Peabody, MA 01960 Dr. Carol Mulrooney Dr. Patrick Gordon Email: [email protected]; Tel: 978-536-2266 Dr. Patricia A. Mabrouk Ms. Meredith Ward Michael P. Filosa, 18 Tamarack Road, Medfield, MA 02052 Ms. Caitlyn Mills Dr. Katherine Rubino Associate Editors: Dr. Anna Sromek Dr. Mariam Ismail Morton Z. Hoffman, 23 Williams Rd., Norton, MA 02766 Dr. Michael Singer Dr. Lori Ferrins Board of Publications: Katherine Lee (Chair), Ajay Purohit, Mary Mahaney, Brian D’Amico, Kather- ine Rubino, Craig Sergeant, Leeanne Minali All Chairs of standing Committees, the editor Business Manager: Vacant: contact Craig D. Sergeant at [email protected] of THE NUCLEUS, and Advertising Manager: Vacant: contact Craig D. Sergeant at [email protected] the Trustees of Section Funds are members of the Calendar Coordinator: Samurdhi Wijesundera, Email: [email protected] Board of Directors. Any Photographers: Brian D’Amico, Morton Z. Hoffman Coun cilor of the American Chemical Society residing within the section area is an ex officio Proofreaders: Michael P. Filosa, Morton Z. Hoffman, Joseph Billo member of the Board of Directors. Copyright 2021, Northeastern Section of the American Chemical Society, Inc. z The Nucleus May 2021 3 New ACS Register NESACS Sponsors Platinum $5000+ Membership Now for the Biogen Options Green Pfizer Sanofi Coming in Chemistry & Gold $3000 up to $5000 AstraZeneca 2022 Engineering Sigma-Aldrich Starting on January 1, 2022, current and Silver $1500 up to $3000 prospective ACS members will be able Conference Bristol-Myers Squibb to choose from new membership pack- th ages that feature different levels of ben- Registration is open for the 25 Green Celgene Chemistry & Engineering (GC&E) efits. No matter where you are in your Jnana Therapeutics academic or professional life, these new Conference. Organized by the ACS options will provide you with more flex- Green Chemistry Institute and the Medimmune Health GC&E Conference Advisory Commit- ibility to choose the package that’s the Bronze $500 up to $1500 best fit for you, and with dues that are tee, this virtual conference will feature lower than they are today. There will more than 38 sessions that will cover a Avinas Operations also be a no-dues option, but which will variety of timely topics, with daily keynote speakers, poster sessions, dedi- Concert Pharmaceuticals include limited benefits.
Load more

Recommended publications
  • Uniqure N.V. Paasheuvelweg 25A 1105BP Amsterdam the Netherlands +1-339-970-7000
    uniQure N.V. Paasheuvelweg 25a 1105BP Amsterdam The Netherlands +1-339-970-7000 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on September 14, 2017 To the Shareholders of uniQure N.V.: Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Extraordinary Meeting”) of uniQure N.V., a public company with limited liability ( naamloze vennootschap ) under the laws of the Netherlands (the “Company,” “uniQure,” and “we”), will be held on September 14, 2017, at 9:30 a.m., Central European Summer Time, at the Company’s principal executive offices located at Paasheuvelweg 25a, 1105BP Amsterdam, the Netherlands, for the following purposes: I. Opening and announcements; II. Appointment of Jeremy P. Springhorn, Ph.D. as a non-executive director (voting proposal no. 1); III. Appointment of Madhavan Balachandran as a non-executive director (voting proposal no. 2); IV Any other business that may properly come before the meeting or any adjournment of the meeting; and V. Closing of the meeting. Each person authorized to attend the Extraordinary Meeting may inspect the Agenda at the office of uniQure. Our Board of Directors (our “Board”) recommends that you vote “FOR” each of the voting proposals noted above. The record date is set at the close of business on August 17, 2017 EST and, therefore, only the Company’s shareholders of record at the close of business on August 17, 2017 EST are entitled to receive this notice (this “Notice”) and to vote at the Extraordinary Meeting and any adjournment thereof. Only shareholders who have given notice in writing to the Company by September 12, 2017 of their intention to attend the Extraordinary Meeting in person are entitled to attend the Extraordinary Meeting in person.
    [Show full text]
  • CB2013 Committee and Board Disclosureauditlist 9.10.13
    2013-2014 Conflict of Interest Disclosure AST Activity Participant First Name Participant Last Name Degree DisclosureDate Disclsoure Item Committee Member Reza Abdi MD 4/22/2013 No Relevant Financial Relationships Committee Member Sameh R. Abul-Ezz MD, PhD 4/16/2013 No Relevant Financial Relationships Committee Member Deborah B. Adey MD 4/15/2013 No Relevant Financial Relationships Committee Member Enver Akalin MD 4/16/2013 Consultant relationship with Pfizer Fellows 2013 Maria-Luisa Alegre MD, PhD 7/12/2013 No Relevant Financial Relationships Committee Member Alessandrini Alessandro PhD 4/29/2013 No Relevant Financial Relationships Board Member James S. Allan MD 5/3/2013 Committee Member No Relevant Financial Relationships Rita R. Alloway PharmD, FCCP Grant Support relationship with Astellas Grant Support relationship with BMS Grant Support relationship with Novartis Grant Support relationship with Lifecycle Grant Support relationship with Millenium Grant Support relationship with Pfizer (previously Wyeth) Grant Support relationship with Genentech (previously Roche) Board Member Grant Support relationship with Viropharma Committee Member Grant Support relationship with Alexion Fellows 2013 7/18/2013 Grant Support relationship with Sanofi (previously Genzyme, previously Sangstat) Committee Member Sandra Amaral MD, MHS 6/18/2013 Other relationship with Bristol Myers-Squibb Hatem Amer MD 5/6/2013 Grant Support relationship with Abbott Laborartories. Committee Member Other relationship with Massacheussetts Medical Society. Committee Member William Applegate No Relevant Financial Relationships Committee Member Alexander Aussi BSN, RN, MBA 4/22/2013 Consultant relationship with Total Transplant Advantage, LLC Committee Member Jamil Azzi MD 4/30/2013 No Relevant Financial Relationships Committee Member Fellows 2013 Mark L.
    [Show full text]
  • Interim Recommendations for Use of the Moderna Mrna-1273 Vaccine Against COVID-19
    Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19 Interim guidance First issued 25 January 2021 Updated 15 June 2021 Background This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) at its extraordinary meeting on 21 January 2021 (1) and updated during its extraordinary meeting on 27 May 2021(2). Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Working Group website. The guidance is based on the evidence summarised in the Background document on the Moderna mRNA-1273 vaccine against COVID-19 (3) and the background paper on COVID-19 disease and vaccines (4). Annexes which include GRADE and evidence-to-recommendations (ETR) tables have also been updated to reflect the updated recommendations. All referenced documents are available on the SAGE COVID-19 webpage: https://www.who.int/groups/strategic- advisory-group-of-experts-on-immunization/covid-19-materials. These interim recommendations refer to the mRNA-1273 vaccine, manufactured by Moderna. The vaccine is also known as COVID-19 Vaccine Moderna. In the subsequent text the vaccine will be referred to as mRNA-1273. On 30 April 2021, mRNA-1273 was granted WHO’s Emergency Use Listing (EUL). Methods SAGE applies the principles of evidence-based medicine and has set in place a thorough methodological process for issuing and updating recommendations (5). A detailed description of the methodological processes as they apply to COVID-19 vaccines can be found in the SAGE evidence framework for COVID-19 vaccines (6).
    [Show full text]
  • Surescripts, Llc As Amicus Curiae in Support of Petitioners in No
    Nos. 19-508 and 19-825 In the Supreme Court of the United States ———————————— AMG CAPITAL MANAGEMENT, LLC, ET AL., Petitioners, v. FEDERAL TRADE COMMISSION, Respondent. ———————————— FEDERAL TRADE COMMISSION, Petitioner, v. CREDIT BUREAU CENTER, LLC, ET AL., Respondents. ———————————— ON WRITS OF CERTIORARI TO THE UNITED STATES COURTS OF APPEALS FOR THE SEVENTH AND NINTH CIRCUITS ———————————— BRIEF OF SURESCRIPTS, LLC AS AMICUS CURIAE IN SUPPORT OF PETITIONERS IN NO. 19-508 AND RESPONDENTS IN NO. 19-825 ———————————— ALFRED C. PFEIFFER, JR. ROMAN MARTINEZ LATHAM & WATKINS LLP Counsel of Record 505 Montgomery Street AMANDA P. REEVES Suite 2000 ALLYSON M. MALTAS San Francisco, CA 94111 DOUGLAS C. TIFFT BLAKE E. STAFFORD JAMES A. TOMBERLIN* LATHAM & WATKINS LLP 555 Eleventh Street, NW Suite 1000 Washington, DC 20004 (202) 637-2200 [email protected] Counsel for Amicus Curiae Surescripts, LLC TABLE OF CONTENTS Page TABLE OF AUTHORITIES ...................................... ii INTEREST OF AMICUS CURIAE ............................1 SUMMARY OF ARGUMENT .....................................3 ARGUMENT ...............................................................5 I. The FTC Has Increasingly Wielded Section 13(b) To Obtain Monetary Relief In Antitrust Cases ................................................5 II. The FTC’s Antitrust Authority Confirms That Section 13(b) Does Not Authorize Monetary Relief ..................................................22 CONCLUSION ..........................................................32 ii TABLE OF AUTHORITIES Page(s) CASES Apple Inc. v. Pepper, 139 S. Ct. 1514 (2019) .......................................... 13 Armstrong v. Exceptional Child Center, Inc., 575 U.S. 320 (2015) .............................................. 23 Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (2007) .............................................. 26 In re Cardinal Health, Inc., No. 101-0006, 2015 WL 1849040 (F.T.C. Apr. 17, 2015) ........................ 19, 20, 28, 30 Credit Suisse Securities (USA) LLC v. Billing, 551 U.S.
    [Show full text]
  • Moderna Vaccine Day Presentation
    Zika Encoded VLP mRNA(s) RSV CMV + EBV SARS-CoV- RSV-ped 2 Flu hMPV/PIV3 H7N9 Encoded mRNA(s) Ribosome Protein chain(s) First Vaccines Day April 14, 2020 © 2020 M oderna Therapeutics Forward-looking statements and disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not limited to, statements concerning; the impact of the SARS-CoV-2 pandemic on the Company’s clinical trials and operations; the timing and finalization of a dose-confirmation Phase 2 study and planning for a pivotal Phase 3 study for mRNA-1647; the status and outcome of the Phase 1 clinical trial for mRNA-1273 being conducted by NIH; the next steps and ultimate commercial plan for mRNA-1273; the size of the potential market opportunity for mRNA-1273; the size of the potential commercial market for novel vaccines produced by Moderna or others; the potential peak sales for the Company’s wholly-owned vaccines; the probability of success of the Company’s vaccines individually and as a portfolio; and the ability of the Company to accelerate the research and development timeline for any individual product or the platform as a whole. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements.
    [Show full text]
  • The Covid–19 Pandemic and Haemoglobin Disorders
    THE COVID–19 PANDEMIC AND HAEMOGLOBIN DISORDERS VACCINATIONS & THERAPEUTIC DRUGS An Informational Guide from the Thalassaemia International Federation (TIF) Prepared by: Dr Androulla Eleftheriou, Executive Director, TIF Last Updated: 12 May 2020 VACCINATIONS & THERAPEUTIC DRUGS Introduction It is important to note that there are currently no FDA1 or EMA2-approved or even recommended agents for the treatment of the novel coronavirus (COVID-19), for which the World Health Organization (WHO) declared as pandemic on Wednesday 11th of March 2020. Any agent being used at this time is being administered in an experimental setting under controlled conditions. Thalassaemia International Federation (TIF) has made an effort to compile a list of studies/clinical trials for treatment and vaccines, which is by no means exhaustive as this situation is extremely labile and research in this area is dramatically intensified. New information is anticipated to be added to this guide which is prepared exclusively for TIF’s global thalassemia community. The viral genome was mapped very soon as rom early January 2020 and shared globally. In February 2020, the WHO published an overview of the potential therapeutic candidates for the treatment of COVID-19. The document outlines 76 regimens that have been proposed (as of February 17, 2020) for the treatment of patients infected with the virus. Thirty-eight of these candidates are in the preclinical state with minimal information available on their proposed mechanism, uses, doses routes, or planned trials. Sixteen of the remaining regimens contain an interferon-based product. The rest include a variety of antimicrobials, corticosteroids, convalescent plasma, and biologics. The Director-General of the WHO, Mr Tedros Adhanom, stated on the 10th of April 2020, that more than 70 countries have joined WHO’s trial to accelerate research on effective treatments and 20 Institutions and companies ‘are racing to develop a vaccine’.
    [Show full text]
  • Federal Register/Vol. 84, No. 232/Tuesday, December 3, 2019
    Federal Register / Vol. 84, No. 232 / Tuesday, December 3, 2019 / Notices 66191 the Assistant Attorney General, patterns, devices, manufacturing filed with and accepted, subject to final developed the HSR Rules and the processes, or customer names. approval, by the Commission, has been corresponding Notification and Report placed on the public record for a period Form. Heather Hippsley, of thirty (30) days. The following On September 11, 2019, the Deputy General Counsel. Analysis to Aid Public Comment Commission sought comment on the [FR Doc. 2019–26075 Filed 12–2–19; 8:45 am] describes the terms of the consent reporting requirements associated with BILLING CODE 6750–01–P agreement and the allegations in the the HSR Rules and corresponding complaint. An electronic copy of the Notification and Report Form. 84 FR full text of the consent agreement 47951. No relevant comments were FEDERAL TRADE COMMISSION package can be obtained from the FTC received. Pursuant to the OMB [File No. 191 0061] Home Page (for November 15, 2019), on regulations, 5 CFR part 1320, that the World Wide Web, at https:// implement the PRA, 44 U.S.C. 3501 et Bristol-Myers Squibb Company and www.ftc.gov/news-events/commission- seq., the FTC is providing this second Celgene Corporation; Analysis of actions. opportunity for public comment while Agreement Containing Consent Orders You can file a comment online or on seeking OMB approval to renew the pre- To Aid Public Comment paper. For the Commission to consider existing clearance for those information your comment, we must receive it on or collection requirements.
    [Show full text]
  • Shire Acquisition of Viropharma - Strategic Move to Strengthen Shire’S Rare Disease Business - Augments Already Strong Growth Prospects
    Shire acquisition of ViroPharma - Strategic move to strengthen Shire’s Rare Disease business - Augments already strong growth prospects Flemming Ornskov, MD Chief Executive Officer Graham Hetherington Chief Financial Officer Our purpose We enable people with life-altering conditions to lead better lives. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements included in this communication that are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that: •Shire’s proposed acquisition of ViroPharma may not be consummated due to the occurrence of an event, change or other circumstances that gives rise to the termination of the merger agreement; •a governmental or regulatory approval required for the proposed acquisition of ViroPharma may not be obtained, or may be obtained subject to conditions that are not anticipated, or another condition to the closing of the proposed acquisition may not be satisfied; •ViroPharma may be unable to retain and hire key personnel and/or maintain its relationships with customers, suppliers and other business partners pending the consummation of the proposed acquisition by Shire, or ViroPharma’s business may be disrupted by the proposed acquisition, including increased costs and diversion of management time and resources; •difficulties in integrating ViroPharma into Shire may lead to the combined company not being able to realize the expected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits at the time anticipated or at all; and risks and uncertainties detailed from time to time in Shire’s or ViroPharma’s filings with the U.S.
    [Show full text]
  • Biopharma R&D on Treatment and Vaccines
    Biopharma R&D on Treatment and Vaccines Coronavirus: Gilead Readies For Remdesivir Ramp Up, Questions On Profit Motive Demand Could Be High For Antiviral Executive Summary “All of that is at risk in not knowing if the drug If clinical trials prove it effective against COVID-19, works or not – and that is really not with an eye to remdesivir could potentially help millions of commercial,” she added. patients - which raises big questions about funding and access. Mercier said the company was spending more time on considering issues of access to the drug once its safety and efficacy is established – especially in regions of the world with less As vaccines will take around 12 months to developed healthcare systems. develop, companies with antiviral treatments are now been pushed to the front line in the battle Nevertheless, Gilead is contemplating a possible against coronavirus, and Gilead Sciences Inc.’s commercial future for the drug. remdesivir is currently the biggest hope of a drug to treat infected patients. “I have to be honest, commercial opportunity might come if this becomes a seasonal disease The company had big news to talk about on 2 or if stockpiling comes into play, but that is much March at the Cowen Health Care conference, as it later down the line,” concluded Mercier. had announced earlier in the day the acquisition of oncology firm Forty Seven for $4.9bn. (Also see One precedent for a big commercial hit for an “Gilead Calls Forty Seven Buyout Complementary antiviral product is Roche’s Tamiflu (oseltamivir). To Kite, Other IO Efforts” - Scrip, 2 Mar, 2020.) The drug achieved peak revenues of $3bn in 2009, largely down to stockpiling in response to that Speaking at the investor conference, Gilead’s chief year’s H1N1 flu pandemic.
    [Show full text]
  • Effectiveness of Pfizer-Biontech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021
    Morbidity and Mortality Weekly Report Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 Mark W. Tenforde, MD, PhD1; Samantha M. Olson, MPH1; Wesley H. Self, MD2; H. Keipp Talbot, MD2; Christopher J. Lindsell, PhD2; Jay S. Steingrub, MD3; Nathan I. Shapiro, MD4; Adit A. Ginde, MD5; David J. Douin, MD5; Matthew E. Prekker, MD6; Samuel M. Brown, MD7; Ithan D. Peltan, MD7; Michelle N. Gong, MD8; Amira Mohamed, MD8; Akram Khan, MD9; Matthew C. Exline, MD10; D. Clark Files, MD11; Kevin W. Gibbs, MD11; William B. Stubblefield, MD2; Jonathan D. Casey, MD2; Todd W. Rice, MD2; Carlos G. Grijalva, MD2; David N. Hager, MD, PhD12; Arber Shehu, MD12; Nida Qadir, MD13; Steven Y. Chang, MD, PhD13; Jennifer G. Wilson, MD14; Manjusha Gaglani, MBBS15,16; Kempapura Murthy, MPH15; Nicole Calhoun, LMSW, MPA15; Arnold S. Monto, MD17; Emily T. Martin, PhD17; Anurag Malani, MD18; Richard K. Zimmerman, MD19; Fernanda P. Silveira, MD19; Donald B. Middleton, MD19; Yuwei Zhu, MD2; Dayna Wyatt2; Meagan Stephenson, MPH1; Adrienne Baughman2; Kelsey N. Womack, PhD2; Kimberly W. Hart2; Miwako Kobayashi, MD1; Jennifer R. Verani, MD1; Manish M. Patel, MD1; IVY Network; HAIVEN Investigators On April 28, 2021, this report was posted as an MMWR Early ≥65 years. Vaccination is a critical tool for reducing severe Release on the MMWR website (https://www.cdc.gov/mmwr). COVID-19 in groups at high risk. Adults aged ≥65 years are at increased risk for severe outcomes Randomized clinical trials of vaccines that have received an from COVID-19 and were identified as a priority group to EUA in the United States showed efficacy of 94%–95% in receive the first COVID-19 vaccines approved for use under preventing COVID-19–associated illness (4,5).§ However, an Emergency Use Authorization (EUA) in the United States hospitalization is a rare outcome among patients with (1–3).
    [Show full text]
  • Package Insert Has Been Approved by the U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION **Doses up to 1,000 U every 3 to 4 days may be considered based on These highlights do not include all the information needed to use individual patient response. ® CINRYZE safely and effectively. See full prescribing information for ---------------------- DOSAGE FORMS AND STRENGTHS -------------------- CINRYZE. Approximately 500 Units (lyophilized) in an 8 mL vial. (3) CINRYZE (C1 Esterase Inhibitor [Human]) ---------------------------- CONTRAINDICATIONS ------------------------------- For Intravenous Use, Freeze-Dried Powder for Reconstitution Patients who have manifested life-threatening immediate hypersensitivity Initial U.S. Approval: 2008. reactions, including anaphylaxis, to the product (4). --------------------------- RECENT MAJOR CHANGES -------------------------- ----------------------------- WARNINGS/PRECAUTIONS ------------------------ • Indications and Usage (1) 06/2018 • Hypersensitivity reactions may occur. Have epinephrine immediately • Dosage and Administration (2.1) 06/2018 available for treatment of acute severe hypersensitivity reaction (5.1) • --------------------------- INDICATIONS AND USAGE --------------------------- Serious arterial and venous thromboembolic (TE) events have been CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against reported at the recommended dose of C1 Esterase Inhibitor (Human) angioedema attacks in adults, adolescents and pediatric patients (6 years of products, including CINRYZE, following administration in patients with age and older)
    [Show full text]
  • Representative Legal Matters Randall B
    Representative Legal Matters Randall B. Sunberg H. Lundbeck A/S in the licensing to Denovo Biopharma of global rights to idalopirdine (an oral 5-HT6 antagonist) for Alzheimer's Disease, schizophrenia and other indications, subject to options for Lundbeck to re-acquire such rights with the parties sharing China rights. Takeda in its strategic collaboration with KSQ Therapeutics to identify optimal T cell and NK cell gene targets screened using KSQ’s CRISPRomics technology and to develop and commercialize novel cell and non-cell immuno-oncology therapies. NBE Therapeutics in its collaboration with Exelixis to discover and develop antibody-drug conjugates for oncology applications. Takeda in the sale to Neuraxpharm of global rights to the prescription brand Buccolam® (indicated for the emergency treatment of epileptic children with prolonged acute convulsive seizures). BeiGene in its collaboration with Assembly Biosciences to develop and commercialize in China, Hong Kong, Macau and Taiwan Assembly’s portfolio of three clinical-stage core inhibitor candidates for the treatment of patients with chronic hepatitis B virus (HBV) infection. GSK Consumer Healthcare in its collaboration with Mammoth Biosciences to develop a rapid, handheld CRISPR-based test to detect novel coronavirus infections. H. Lundbeck A/S in the acquisition of Alder BioPharmaceuticals, Inc, a company committed to migraine treatment and prevention, a transaction valued at USD 1.95 billion. Galapagos in its transformative USD 5.1 billion research and development collaboration
    [Show full text]